{"id":6999,"date":"2026-05-05T10:00:02","date_gmt":"2026-05-05T16:00:02","guid":{"rendered":"https:\/\/allphasepharma.com\/dir\/?p=6999"},"modified":"2026-05-05T10:00:06","modified_gmt":"2026-05-05T16:00:06","slug":"the-tiragolumab-saga-tifacogin-flash-backs","status":"publish","type":"post","link":"https:\/\/allphasepharma.com\/dir\/2026\/05\/05\/6999\/the-tiragolumab-saga-tifacogin-flash-backs\/","title":{"rendered":"The Tiragolumab Saga & Tifacogin Flash-Backs"},"content":{"rendered":"\n
\"\"<\/a><\/figure>\n\n\n\n

A recent Nature Review Drug Discovery article caught our attention, a review of TIGIT as an IO target and the failed Phase 3 study of tiragolumab which is the TIGIT inhibitor from Roche.[1]<\/a> \u00a0The science writer interviewed a group of insiders that had a lead role in the development of the drug and deep understanding of its MoA.\u00a0 No doubt these researchers have insights and experiences to share about things gone right and things done wrong.\u00a0<\/p>\n\n\n\n

In corporate speak, this is called a \u2018teaching moment\u2019 or a \u2018Lessons Learned\u2019 exercise.  In medicine, we have something similar, the post-mortem or M&M conference. The declared goal for either is pretty much the same: Learn from mistakes in order to avoid them in the future.<\/p>\n\n\n\n

If you expected advice along these lines for TIGIT as a target in general and tiragolumab development in particular, you\u2019d be disappointed, because that\u2019s not what we get served in the article.\u00a0 This is not the interviewer\u2019s fault but a systematic unwillingness to openly review a decision process that did not end with the desired outcome.<\/p>\n\n\n\n

This article provides a rather superficial apology for the millions of dollars spent on the development of tiragolumab and the billions of dollars spent by companies trolling the TIGIT target.  It tells the history of tiragolumab: its promising research beginnings, Phase 2 success, and the unexpected failure in the pivotal Phase 3 study.  The key question \u201cWhat exactly went wrong\u201d is answered only in generic ways, with some platitudes mixed in for good measure.<\/p>\n\n\n\n

This biological, brainchild of Roche\/Genentech, made sense scientifically and biologically.  Promising preclinical and excellent Phase 2 data suggested benefit in NSCLC. With seemingly compelling results in the CITYSCAPE Phase 2 trial [2]<\/a>, the project really took off at Roche. The competition did not want to miss out on the next blockbuster and was quick to jump on the TIGIT bandwagon. <\/p>\n\n\n\n

Paired with a PD-1 inhibitor for synergistic efficacy in NSCLC , tiragolumab was seen as a potential blockbuster drug for Roche\u2019s oncology portfolio.<\/p>\n\n\n\n

\n
Corporate risk-taking has become even more the norm since 
the PD-1 race, when BMS\u2019s nivolumab lost out to Merck\u2019s pembrolizumab. 
Following the Perlmutter \/ Merck example, tiragolumab was developed 
like the second coming of pembrolizumab. <\/pre>\n<\/blockquote>\n\n\n\n
Alas, it was not to be…like Icaros, tiragolumab\u2019s wings came too close to the sun.  When projects fail late and unexpectedly, soul-searching starts, right?  Well, not really.<\/p>\n\n\n\n
Companies write off the losses of a failed program, lick their wounds, then move on quickly and reorganize.  Frankly, they don\u2019t spend much time on \u2018Lessons Learned\u2019; after all, it would be a painful exercise for the protagonists of the project and decision makers still around.  <\/p>\n\n\n\n
Corporate managers cannot divulge learnings; they are insiders and contractually held to confidentiality.\u00a0 Hence, the \u201cLearnings\u201d in the Nature article are generic, decrying \u201cthe heterogeneity of cancer and the complexity of the human immune system\u201d.\u00a0 True, but we know that already!<\/p>\n\n\n\n
Here we summarize the \u2018TEACHINGS\u2019 taken directly from the Nature article; 
OUR COMMENTS and \u2018LEARNINGS\u2019 in BLUE<\/mark>:<\/p>\n\n\n\n
\"\"<\/a><\/figure>\n\n\n\n
\"\"<\/a><\/figure>\n\n\n\n
It is our firm belief that the Phase 2 \u201cHigh PD-1\u201d analyses should have been treated as hypothesis-generating, to be confirmed in a new Phase 2 trial.  This subset population should never have become the basis of a large pivotal Phase 3 trial like SKYSCRAPER. <\/p>\n\n\n\n
\"\"<\/a>
CITYSCAPE data.  From: Cho B.  Lancet Oncology 2022 <\/figcaption><\/figure>\n\n\n\n
SKYSCRAPER-01 enrolled 534 patients with \u201cHigh PD-L1\u201d- NSCLC in an attempt to confirm the subset data from Phase 2.  We are not at all surprised that this trial failed; the entire program was subsequently stopped.[1]<\/a>,[2]<\/a><\/p>\n\n\n\n
Actually, Roche\u2019s decision to use data from an exploratory subset as the basis for a pivotal trial is a common mistake.  We still remember tifacogin, the TFPI inhibitor program from Chiron\/Novartis.  In that program, a Phase 2 study in severe sepsis (OPTIMIST) showed little benefit, but a retrospective analysis of the trial identified a subset of septic patients with \u2018CABP\u2019 that seemed to benefit from tifacogin.  This factoid clinched it for corporate decision-makers at Chiron.  They embarked on a 2,100 patient Phase 3 program in septic CABP patients study called CAPTIVATE.  It failed.[5]<\/a>,[6]<\/a><\/p>\n\n\n\n
The tifacogin \/ TIFPI program was a LEARNING experience and a TEACHING moment for all involved (it was not reviewed in Nature at the time).<\/p>\n\n\n\n
The Roche : Novartis score now stands at an even 1:1.   We hope this game of blunders does not go into overtime!<\/p>\n\n\n\n
\n\n\n\n
REFERENCES<\/strong>
[1]<\/a> Mullard A. TIGIT\u2019s immuno-oncology teachings.  Nature Reviews Drug Discovery 2026; 25: 157
[2]<\/a> Cho B. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol 2022; 23: 781
[3]<\/a> PR Roche Nov 25, 2024.  Roche reports update on Phase III SKYSCRAPER-01 study results<\/a> (accessed 4\/18\/2026)
[<\/a>4<\/a>]<\/a> Peters S.  Abstract CT051: SKYSCRAPER-01: A phase III, randomized trial of tiragolumab (tira) + atezolizumab (atezo) versus placebo (pbo) + atezo in patients (pts) with previously-untreated PD-L1-high, locally advanced unresectable\/metastatic NSCLC.  Cancer Res<\/em> (2025) 85 (8_Supplement_2): CT051. https:\/\/doi.org\/10.1158\/1538-7445.AM2025-CT051<\/a>
[5]<\/a> Abraham E. Efficacy and Safety of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) in Severe Sepsis. A Randomized Controlled Trial.  JAMA 2003;290:238
[6]<\/a> Laterre P.  A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia.  Critical Care <\/em>2009, 13<\/strong>: R36 (doi:10.1186\/cc7747).  http:\/\/ccforum.com\/content\/13\/2\/R36
<\/p>\n\n\n\n
\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
ABBREVIATIONS<\/strong>
IO\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 immuno-oncology
ITIM\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Immunoreceptor\u00a0Tyrosine-based\u00a0Inhibitory\u00a0Motif
M&M\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0 morbidity & mortality
NSCLC\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 non-small cell lung cancer
TFPI\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Tissue Factor Pathway Inhibitor
TIGIT\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 T-cell immunoreceptor with Ig and ITIM domain<\/p>\n\n\n\n
<\/p>\n","protected":false},"excerpt":{"rendered":"
A recent Nature Review Drug Discovery article caught our attention, a review of TIGIT as an IO target and the failed Phase 3 study of tiragolumab which is the TIGIT inhibitor from Roche.[1] \u00a0The science writer interviewed a group of insiders that had a lead role in the development of Continue reading   The Tiragolumab Saga & Tifacogin Flash-Backs<\/span>→<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":7008,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[227,3,18],"tags":[1271,2639,796,442,175,2645,1938,1583,2212,2049,588,174,2644,2649,2642,2643,2050,184,2648,262,2646,2647,703,681,2641,2640,2650],"class_list":["post-6999","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-recent_literature","category-the_news","category-the_viewpoint","tag-allphase-pharma-consulting","tag-atezolizumab","tag-bms","tag-cap","tag-chiron","tag-cityscape-trial","tag-genentech","tag-harald-reinhart","tag-igan","tag-keytruda","tag-merck","tag-novartis","tag-nsclc","tag-opdivo","tag-pd-1-inhibitor","tag-pd-l1-inhibitor","tag-pembrolizumab","tag-roche","tag-roger-perlmutter","tag-sepsis","tag-skyscraper-01-trial","tag-tecentriq","tag-tfpi","tag-tifacogin","tag-tigit","tag-tiragolumab","tag-tissue-factor-pathway-inhibitor"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/04\/Tiragolumab-SLIDER-e1776724749732.jpg?fit=640%2C180&ssl=1","jetpack_shortlink":"https:\/\/wp.me\/p4KWFr-1OT","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":1981,"url":"https:\/\/allphasepharma.com\/dir\/2015\/10\/05\/1981\/polyphor-pol-7080-and-the-journey-to-the-land-of-pyocyanea-part-1\/","url_meta":{"origin":6999,"position":0},"title":"Polyphor POL7080 And The Journey to The Land of Pyocyanea\u00a0 (Part 1)","author":"Harald","date":"October 5, 2015","format":false,"excerpt":"When Roche inlicensed Polyphor\u2019s anti-pseudomonas drug POL7080 in November 2013, it marked a turning point. It seemed that Big Pharma that had all but abandoned the field in the last decade and was getting engaged in anti-infectives again. When a company with as\u00a0much experience in antibiotic drug development as Roche\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"bridge Pyocyanea copy","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/10\/bridge-Pyocyanea-copy.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/10\/bridge-Pyocyanea-copy.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/10\/bridge-Pyocyanea-copy.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":1140,"url":"https:\/\/allphasepharma.com\/dir\/2014\/11\/17\/1140\/two-new-approaches-for-dealing-with-sepsis-toxemia\/","url_meta":{"origin":6999,"position":1},"title":"Two New Approaches For Dealing with Sepsis \/ Toxemia","author":"Harald","date":"November 17, 2014","format":false,"excerpt":"There is hardly an indication which has accumulated more failed clinical trials than the sepsis area.\u00a0 Called first bacteremia, later sepsis, sepsis syndrome or septic shock, there have been numerous attempts to influence the cascade of events that eventually lead to MSOF and death.\u00a0 While it is convenient to think\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/11\/sepsis-slider.jpg?fit=640%2C200&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/11\/sepsis-slider.jpg?fit=640%2C200&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/11\/sepsis-slider.jpg?fit=640%2C200&ssl=1&resize=525%2C300 1.5x"},"classes":[]},{"id":1561,"url":"https:\/\/allphasepharma.com\/dir\/2015\/06\/17\/1561\/treating-gc-in-the-face-of-dwindling-antibiotic-options-2\/","url_meta":{"origin":6999,"position":2},"title":"Treating GC in the Face of Dwindling Antibiotic Options \u2013 (2)","author":"Harald","date":"June 17, 2015","format":false,"excerpt":"For GC antibiotics, the development path looks like a trip down the road less traveled, leading into some uncharted territory. Let\u2019s take Melinta\u2019s statement\u00a0[1] at face value according to which the single 900 mg dose of delafloxacin failed because of \"insufficient efficacy\". So, what then determines efficacy? \u00a0Delafloxacin's MIC90 was\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"GC MIC formula","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/06\/GC-MIC-formula.jpg?resize=350%2C200","width":350,"height":200},"classes":[]},{"id":1279,"url":"https:\/\/allphasepharma.com\/dir\/2015\/02\/23\/1279\/discontinued-but-not-forgotten-hcv-drugs-that-did-not-make-it\/","url_meta":{"origin":6999,"position":3},"title":"Discontinued But Not Forgotten: HCV Drugs That Did Not Make It","author":"Harald","date":"February 23, 2015","format":false,"excerpt":"I find it useful to look back and review drug candidates that were stopped in development.\u00a0 In case of insufficient efficacy, i.e., not enough of a VL reduction or early viral rebound, everyone can sympathize with the decision to discontinue a drug. More importantly, we want to learn about the\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"Commandments","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/02\/Commandments.jpg?resize=350%2C200","width":350,"height":200},"classes":[]},{"id":2911,"url":"https:\/\/allphasepharma.com\/dir\/2016\/11\/25\/2911\/prospecting-antibiotics\/","url_meta":{"origin":6999,"position":4},"title":"Prospecting for New Antibiotics","author":"Harald","date":"November 25, 2016","format":false,"excerpt":"The QIDP designation was introduced in 2012 to incentivize drug development in antiinfectives. QIDP came with several attractive features, such as prolongation of patent life, FDA\u00a0expedited review and more.\u00a0 In addition, FDA made it quite easy to garner the label.\u00a0 As you can see, there is really no downside to\u2026","rel":"","context":"In "Did you know...?"","block_context":{"text":"Did you know...?","link":"https:\/\/allphasepharma.com\/dir\/category\/interesting_facts\/"},"img":{"alt_text":"engine-qidp-blog","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/11\/Engine-QIDP-blog.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/11\/Engine-QIDP-blog.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/11\/Engine-QIDP-blog.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":2205,"url":"https:\/\/allphasepharma.com\/dir\/2015\/12\/23\/2205\/qidp-antibiotics-2015-year-end-update\/","url_meta":{"origin":6999,"position":5},"title":"QIDP Antibiotics  –  2015 Year-End Update","author":"Harald","date":"December 23, 2015","format":false,"excerpt":"Here an updated listing of all QIDP drugs we are aware of as of 12\/24\/2015. Today just\u00a0facts and numbers; we will provide an interpretation of the current landscape in upcoming blogs. There are\u00a058 drugs which garnered QIDP status and these are listed in the Main Table below. With the recent\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/12\/QIDP-slider.jpg?fit=640%2C200&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/12\/QIDP-slider.jpg?fit=640%2C200&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/12\/QIDP-slider.jpg?fit=640%2C200&ssl=1&resize=525%2C300 1.5x"},"classes":[]}],"jetpack_likes_enabled":true,"_links":{"self":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/6999","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/comments?post=6999"}],"version-history":[{"count":17,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/6999\/revisions"}],"predecessor-version":[{"id":7145,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/6999\/revisions\/7145"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media\/7008"}],"wp:attachment":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media?parent=6999"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/categories?post=6999"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/tags?post=6999"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}